Reporter brief
Evaluation of the Efficacy of Natural Senolytic Agents and NLRP3 Inhibitors in Treatment of Osteoarthritis: Randomized, Double Blinded ,Placebo Controlled Trial
What happened
Trial registry update: SUSPENDED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report the actual results—whether senolytics reduced pain, effusion volume, or any other measured outcomes—so efficacy cannot be assessed from this text alone.
- Single-center design at one Egyptian hospital limits generalizability to other populations or healthcare settings.
- Natural product formulations have variable composition and bioavailability; results do not clarify which component(s) drove any observed effect.
Study design and sample
Rct; Human.
60 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis
- Design
- Rct
- Sample
- 60
- Journal
- Assiut University
- Published
- Jul 25, 2023
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.